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Finding the Pill on the Floor: 
How Contrast Sensitivity Affects 




lzheimer’s disease (AD) is a progressive brain disorder that gradually 
destroys an individual’s mental functioning and social capabilities, 
including the ability to carry out everyday activities. Although memory 
deﬁcits affect AD patients’ ability to perform these activities, research 
suggests that visual perception impairments also contribute. One impaired visual 
perception ability, contrast sensitivity, enables one to distinguish an object from 
its immediate surroundings. The present project measured contrast sensitivity in 
a real-world task by having AD patients ﬁnd a pill of various shades of gray on a 
tiled background. Results were compared to young and elderly control participants. 
Participants also ﬁlled out a questionnaire examining activities of daily living 
(ADLs). Results demonstrated that impairments in contrast sensitivity were 
observed both as a function of normal aging and as a result of AD. Performance 
correlated with the ADLs of household care and travel for both groups. Increasing 
contrast in environmental settings may aid these individuals, especially AD 
patients, in living a more independent lifestyle. 
Research Question
How does the manipulation of contrast affect Alzheimer’s disease patients’ 
ability to detect a pill on a white-tiled surface? Do these ﬁndings relate to 
problems in activities of daily living experienced by these patients?
Introduction
General Introduction. Alzheimer’s disease (AD) is a progressive brain disorder 
that gradually destroys an individual’s mental functioning and social 
capabilities, including memory, reasoning, decision-making, communication, 
and the ability to carry out everyday activities. According to the Alzheimer’s 
Association, AD affects approximately 4.5 million Americans annually. By 
the year 2050, this number is expected to increase to 11.3 to 16 million. 
Although memory deﬁcits are a primary symptom of AD and the one most 
often researched, other abilities including those in visual perception are also 
impaired (Cronin-Golomb, A., 1995; Gilmore, G. C., Cronin-Golomb, A., 
Neargarder, S., & Morrison, S. R. 2005; Mendola, J. D., Cronin-Golomb, 
A., Corkin, S. & Growdon, J. H., 1995; Neargarder, S. 2005).  One impaired 
ability known as contrast sensitivity has direct implications for the ability of 
AD patients to carry out everyday activities. Contrast sensitivity is deﬁned as 
the smallest difference in intensity that a person can resolve between an object 
and its immediate surroundings. For example, what shade of gray would an 
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electrical outlet need to be before a patient could detect it against 
a white wall? Research shows that deﬁcits in contrast sensitivity 
directly affect everyday activities such as food and liquid intake 
(Dunne, Neargarder, Cipolloni, & Cronin-Golomb, 2004) 
object detection (Neargarder & Cronin-Golomb, 2005), 
and face discrimination (Cronin-Golomb, Cronin Golomb, 
Dunne, Brown, & Jain, 2000).
Background. A number of research studies have identiﬁed 
contrast sensitivity impairments in AD patients (Cronin 
Golomb, Growden, & Corkin, 1995; Cronin-Golomb, 
Gilmore, Neargarder, Morrison, & Laudate, 2007). Results 
from these studies were obtained in a laboratory setting using 
a series of clinical vision charts such as the Vistech and the 
FACT (Functional Acuity Contrast Test). These tests allow 
one to measure contrast deﬁcits across a range of different 
spatial frequencies. Results show that AD patients exhibit 
contrast deﬁcits across all levels of spatial frequency. This 
would potentially make it difﬁcult for patients to distinguish 
between people, places, and things in a real-world environment. 
Although research has demonstrated that deﬁcits measured in 
a laboratory setting using vision charts relate to deﬁcits in the 
real-world, we have no direct measure of contrast sensitivity 
in real-world tasks. For example, although we may know that 
patients will do better in a high-contrast task (pouring milk 
into a black mug) than a low-contrast task (pouring milk into 
a white mug), we do not know what the contrast between the 
two items (milk and cup) needs to be in order for the patient 
to succeed at this task.
Present Project. The present project aimed to measure contrast 
sensitivity in a real-world task by having AD patients ﬁnd pills 
of various shades of gray on a tiled background (simulating a 
white-tiled ﬂoor). This method allowed us to ﬁnd the exact 
contrast the pill needs to be to the background in order for 
patients to be able to successfully ﬁnd the pill. These ﬁndings 
were then compared to a questionnaire that measured general 
activities of daily living. This enabled us to compare laboratory 
based tests to everyday functioning. The results from this study 
aim to increase the functional independence of AD patients, 
both in the home environment and nursing home facilities. 
This increase in independence can result in reducing health 
care costs and increase the overall well-being of patients.  
Methodology
Participants. This study consisted of 15 patients with 
AD, 13 healthy elderly control participants (EC) and 25 
young participants (YC). EC participants were community 
volunteers and AD patients were recruited from Community 
Family Incorporated (AD day programs) located in Lowell 
and Medford, Massachusetts. Participants were matched on 
education, age, and near acuity. 
Materials and Procedures. Materials consisted of a questionnaire 
that measured activities of daily living, and four conditions that 
measured the ability of participants to identify a pill of varying 
contrast levels on a tiled surface. Each measure is described in 
detail below.
Questionnaire. The Activities of Daily Living Scale (ADL) was 
given to each participant and his/her caregiver or informant. 
The ADL scale consists of 28 items that cover areas of self-care, 
household care, employment/recreation, shopping/money, and 
travel/communication. 
Pill Study. The pill study consisted of four different conditions. 
Two of these conditions were naturalistic and two were 
computerized. When conducting research with patient 
populations it is often the case that researchers use computerized 
stimuli to measure abilities and then generalize these ﬁndings 
to the real-world. It is unclear, however, whether one can make 
direct statements about real-world abilities based on these 
artiﬁcial measurements. One goal of this study was to compare 
performance on computerized assessments to performance on 
comparable naturalistic assessments. As such, two naturalistic 
conditions were developed. The ﬁrst used a real pill on a real 
background (N1: completely naturalistic), while the second used 
a printed pill on a real background (N2: partially naturalistic). 
The contrast of the pill to the background was identical in 
both conditions. The ﬁrst computerized condition (C1) was 
perceptually identical to condition N2 (contrast values are 
identical, luminance values are different), except it was presented 
on a computer, whereas the second computerized condition 
(C2) was physically similar to condition N2 (both contrast and 
luminance values were similar) but was perceptually different 
than N2. The rationale for including these four conditions was 
to aid in differentiating the factors that contribute to the ability 
of an Alzheimer’s patient to detect an object of varying shades 
of contrast on an identiﬁed surface and to determine whether 
performance differed between computerized and naturalistic 
assessments. Each of the four conditions used seven pills of 
varying shades measured using a Minolta CS-100 photometer. 
Shade one was the lightest and the hardest to see and shade 
seven was the darkest and the easiest to see. The luminance 
of each of the seven pills was measured against the luminance 
of the tiled background to result in seven different contrast 
levels per condition. For all conditions, the contrast of the pill 
relative to the background ranged from 1.2% to 6.6%.
Naturalistic Version 1(real pill: N1). In this version, pills were 
created to emulate a 10 mg donepezil HCL tablet. This drug 
is commonly prescribed to individuals with AD. Pills were 
presented on an 8.5’’ x 11” piece of paper printed with a six 
by six grid comprised of 36 squares meant to represent a tiled 
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background. Each of the seven pills was presented randomly 
four times per quadrant for a total of 112 trials. A white 
screen was used to conceal the placement of the pill from the 
participant before each trial. Participants were instructed to 
locate and touch the pill as quickly as possible. Reaction times 
were recorded.
 
Naturalistic Version 2 (printed pill: N2). In this version, pills 
were printed onto a tiled background; real pills were not used. 
The background from N1 remained the same. A photometer 
was used to verify the contrast values. Trials were bound using 
3 binders and were presented to participants by ﬂipping the 
pages like a book. Like in N1, 112 trials were presented and 
reaction times were recorded. 
Computerized Version 1 (high luminance: C1).Using Adobe 
Photoshop, trials perceptually similar to both N1 and N2 
were created. The same counterbalancing and randomization 
from conditions N1 and N2 were used and presented on a 
calibrated touch screen monitor using Superlab 4.0. This 
program recorded the area touched by the participant and 
reaction times. 
 
Computerized Version 2 (low luminance: C2). A different 
computerized version was created with the luminance and 
contrast values similar to the naturalistic versions. Again 
contrast values of the pills were consistent with those used in 
C1. Randomization, counterbalancing and presentation were 
also consistent with C1. Reaction time was measured using 
Superlab 4.0. 
Results
Reaction time data were analyzed by using mixed design 
analyses of variance followed by a priori comparisons using 
an adjusted alpha level for each condition. Correlational 
analyses were also performed between the pill reaction time 
data and the ADL scale. Any and all violations regarding the 
use of parametric statistics were properly addressed. For ease of 
presentation, results are displayed graphically using symbols to 
indicate signiﬁcant differences between groups. Results of all of 
the individual analyses are not listed. 
Naturalistic Version 1(real pill: N1). For normal aging (YCs 
versus ECs), there were no signiﬁcant differences in reaction 
time across the seven contrast levels. However, AD patients 
differed from EC participants at all contrast levels (see Figure 
1).
Naturalistic Version 2 (printed pill: N2). For normal aging 
(YCs versus ECs), there were signiﬁcant differences in slower 
latency times in contrast levels two through six. However, AD 
participants compared to ECs showed signiﬁcant differences 
for levels two through ﬁve, no differences were noted at levels 
six or seven (see Figure 2).
Computerized Version 1 (high luminance: C1). For normal aging 
(YCs versus ECs), there were signiﬁcant differences in reaction 
time across contrast levels two through seven. AD participants 
when compared to ECs did not show signiﬁcant differences 
across any of the seven contrast levels (see Figure 3).
Computerized Version 2 (low luminance: C2). For normal aging 
(YCs versus ECs), there were differences in reaction time across 
contrast levels three through seven. When AD patients were 
compared to ECs there were differences across contrast levels 
three through seven. (see Figure 4).
Everyday Functioning Questionnaire. For both AD and EC 
groups, signiﬁcant positive correlations were noted between 
RT performance and the ADLs of household care and travel.
Discussion 
In regards to normal aging, results indicated that EC perfor-
mance when compared to YC performance was signiﬁcantly 
slower for the printed pill (N2), computerized high (C1), and 
computerized low (C2) conditions. Most likely, the additive ef-
fect of decreased contrast across conditions and low-luminance 
stimuli resulted in poorer performance; the EC had more dif-
ﬁculty seeing the pills.  Both YC and EC performance was 
similar on the Real Pill (N1) condition; this suggests that the 
cue of depth and the naturalism of the stimuli enhanced the 
detection of the object despite low luminance. An implication 
of the Naturalistic 3-D Pill appears to be that for a nearby and 
a non-cultured real world assessment, depth is a strong indica-
tor of performance and that in some cases, if depth is present, 
contrast deﬁcits may be minimized.  These ﬁndings were also 
related to the ADLs of household care and travel. Taken to-
gether, these results support the ﬁndings that EC individuals 
demonstrate impairments in contrast sensitivity and that these 
impairments directly relate to real-world functioning.
When compared to the EC group, individuals with AD 
exhibited slower latency times on all pill conditions except for 
the Computer High-Luminance condition (C1). The lack of a 
signiﬁcant difference between EC and AD individuals for this 
condition was most likely due to the added beneﬁt of increased 
luminance provided by the computer monitor. Though they 
did not make any errors on the Naturalistic 3-Dimensional 
Pill (N1), they were slower than the EC group at all contrast 
levels. Differences in performance were also observed for the 
Computer Low-Luminance Condition (C2). In general, the 
AD group exhibited slower reaction times than the EC group 
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across contrast levels most likely due to the low luminance and 
contrast levels of the stimuli. 
  
An interesting pattern emerged for the Naturalistic Printed-
Pill condition (N2). Here, differences between the AD and 
EC participants were observed at the lower contrast levels but 
not the higher ones (contrast levels 6 and 7). At these levels, 
the AD and EC participants exhibited similar reaction times. 
These results suggest that in certain conditions, if the contrast 
of the stimuli is high enough, performance differences between 
groups disappear.  Overall, ﬁndings suggest that by increasing 
the luminance and contrast of stimuli, one can potentially 
compensate for contrast sensitivity losses noted in the AD 
population. Similarly to the EC group, ﬁndings were related to 
the ADLs of household care and travel thereby suggesting that 
losses in contrast sensitivity relate to everyday functioning.
These results suggest that individuals with AD exhibit 
contrast deﬁcits beyond those that occur with normal aging. 
These deﬁcits most likely impair their ability to function 
independently. In addition, results tend to differ depending 
on a variety of factors including the overall luminance of 
the stimuli used, the contrast of the stimuli when compared 
to a background, and whether the stimuli are presented in a 
naturalistic or computerized form. All of these things should be 
taken into account when generalizing laboratory results to real-
world conditions. Finally, by examining the results of the four 
conditions, one can pinpoint where performance falls off for AD 
patients. This information can be used to create environments 
that help to minimize the visual deﬁcits experienced by these 
patients.
Interventions to improve visual function, speciﬁcally contrast 
enhancement and increased luminance, may be of practical 
use in improving the everyday functioning of older adults. 
For example, it may be of use for individuals when managing 
their medications. If the right level of contrast is used in the 
environment wherein individuals with AD reside, they will 
be better able to detect pills on a surface which will increase 
medication adherence. Increasing contrast in environmental 
settings can aid AD patients in living a more independent 
lifestyle. 
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Figures
For each of the ﬁgures that follow, reaction time (in log units) 
is plotted as a function of Michleson contrast values (also in 
log units). Each of the seven data points represent the mean 
reaction time for that contrast level. From left to right, the 
contrast levels are given in order ranging from contrast level 1 
(the most difﬁcult to see) to contrast level 7 (the easiest to see). 
Vertical bars represent the standard error of the mean for each 
condition. Results are plotted for the YC, EC, and AD groups. 
The symbol ‘†’ represents a signiﬁcant difference between the 
YC and EC groups and the symbol ‘*’ represents a signiﬁcant 
differnce between the EC and AD groups. 
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